NCT05733533已完成2 期
A Multicenter, Randomized, Double-blind, Parallel, Placebo-controlled Phase II Study of Efficacy and Safety of HRS-2261 in Refractory Chronic Cough
Guangdong Hengrui Pharmaceutical Co., Ltd1 个研究点 分布在 1 个国家目标入组 97 人开始时间: 2023年3月9日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 97
- 试验地点
- 1
- 主要终点
- Changes from baseline in visual analog Scale (VAS) scores of cough severity after 4 weeks of treatment (Day 28)
研究概览
简要总结
This is a phase II study that will investigate the efficacy, safety and tolerability of HRS-2261 in subjects with refractory chronic cough using a double blind, placebo controlled, randomized study design.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •≥18 years of age;
- •Diagnosed with refractory chronic cough or chronic cough of unknown cause, with a course of disease lasting more than 1 year;
- •Within 5 years prior to screening and after the onset of chronic cough, chest imaging did not reveal any significant abnormalities that the investigators considered to cause chronic cough or any other clinically significant lung disease;
- •VAS scores of cough severity in screening period and baseline period ≥ 40 mm;
- •Subjects receiving medication for pre-existing underlying conditions prior to the screening period should stabilize the corresponding dose for at least 8 weeks prior to screening;
- •Take effective contraceptive measures;
- •Voluntarily sign informed consent to participate in this study;
- •Willing and able to comply with all protocol requirements, including demonstrating the ability to comply with study procedures prior to random assignment.
排除标准
- •Patients diagnosed with chronic obstructive pulmonary disease (COPD), bronchiectasis, idiopathic pulmonary fibrosis (IPF), and endobronchial tuberculosis;
- •Patients with a history of chronic bronchitis;
- •Patients with a history of upper or lower respiratory tract infection, or acute exacerbation of respiratory disease, or significant changes in chest imaging within 4 weeks prior to baseline period;
- •Current smokers, smokers who have quit smoking (within 6 months), or former smokers who consume more than 20 packs of cigarettes per year;
- •Those with abnormal taste within 3 months prior to previous diagnosis or screening;
- •Malignant disease within 5 years or less before signing the informed consent, except for basal cell or squamous cell skin cancer or cervical cancer in situ after appropriate treatment;
- •Currently taking or having taken an angiotensin-converting enzyme inhibitor in the 3 months prior to screening;
- •Those who are currently taking or have used any antitussive medication within the week prior to screening;
- •Patients who had used oral steroids or antiallergy drugs within 1 week prior to screening;
- •Screening or baseline 1 second rate < 60%;
- •Poorly controlled hypertension;
- •Alanine aminotransferase or aspartate aminotransferase more than 2 times the upper limit of normal in screening period or baseline period;
- •Estimated glomerular filtration rate (eGFR) < 30mL/min/1.73m2 or eGFR≥30mL/min/1.73m2 and <50mL/min/1.73m2 with unstable renal function during screening;
- •Use of systemic immunosuppressants or immunomodulators, or biologics or Th2 cytokine inhibitors within 12 weeks prior to randomization or within 5 half-lives of the drug;
- •A recent history of drug or alcohol abuse or dependence (within the past 1 year);
- •Participants enrolled in clinical trials of any drug or medical device within 3 months prior to screening, or within 5 half-lives of test drugs before screening, whichever is longer;
- •Any past or present circumstances, determined by the investigator or sponsor, make the subject unfit for admission to the study.
研究组 & 干预措施
HRS-2261 oral tablet
Experimental
干预措施: HRS-2261 oral tablet (Drug)
Matching placebo to HRS-2261
Placebo Comparator
干预措施: Matching placebo to HRS-2261 (Drug)
结局指标
主要结局
Changes from baseline in visual analog Scale (VAS) scores of cough severity after 4 weeks of treatment (Day 28)
时间窗: Baseline (Day-1)，Day 28
次要结局
- Changes from baseline in the total score of the Leicester Cough Questionnaire (LCQ), which assessed cough-specific quality of life, at 2 and 4 weeks after treatment (Day 14, Day 28)(Baseline (Day-1), Day 14, Day 28)
- Changes from baseline in the simple cough severity score (CET) at week 1, 2, 3, and 4 after treatment (Day 7, Day 14, Day 21, Day 28)(Day 7, Day 14, Day 21, Day 28)
- Incidence and severity of any adverse events (AE)(up to 6 weeks (Day 42))
- Changes from baseline in patients' overall Impression of Change (PGIC) scale scores after week 1, 2, 3 and 4 of treatment (Day 7, Day 14, Day 21, Day 28)(Day 7, Day 14, Day 21, Day 28)
研究者
研究点 (1)
Loading locations...
相似试验
招募中
2 期
A Trial of SHR-A2102 for Treatment of Advanced Gynecological MalignancyAdvanced Gynecological MalignancyNCT06654440Shanghai Hengrui Pharmaceutical Co., Ltd.100
Unknown
2 期
A Trial of HR021618 in Postsurgical Pain ManagementPostsurgical Pain ManagementNCT04699175Jiangsu HengRui Medicine Co., Ltd.108
招募中
1 期
A Trial of SHR-A2102 With Adebrelimab With or Without Other Antitumor Therapy in Advanced or Metastatic Non-small Cell Lung CancerAdvanced or Metastatic Non-small Cell Lung CancerNCT06512051Shanghai Hengrui Pharmaceutical Co., Ltd.248
招募中
1 期
A Trial of SHR-A2102 With Adebrelimab With or Without Other Antitumor Therapy in Advanced or Metastatic Esophageal CancerAdvanced or Metastatic Esophageal CancerNCT06474468Shanghai Hengrui Pharmaceutical Co., Ltd.148
尚未招募
2 期
Clinical Study of SHR-A1921 or SHR-A2009 in Previously Treated Advanced NSCLCNSCLCNCT06465238Henan Cancer Hospital30